Torigen Pharmaceuticals CEO Ashley Kalinauskas Recognized in Forbes 30 Under 30
Founder of company working to eradicate pet cancer honored in science category
FARMINGTON, Conn., Dec. 10, 2019 /PRNewswire-PRWeb/ -- Torigen Pharmaceuticals Inc., a commercial-stage companion animal immuno-oncology company, today announced that its founder and CEO, Ashley Kalinauskas, has been named to the 2020 Forbes 30 Under 30, the annual listing of top young business leaders and entrepreneurs. Kalinauskas was recognized for her work toward developing an affordable cancer treatment for dogs.
"It is truly an honor to be included in such a prestigious list and a testament to the hard work and sacrifice of my dedicated team," said Ashley Kalinauskas, CEO, Torigen. "I'm very grateful for the opportunity to play a part in bringing this revolutionary solution to pet owners to make cancer treatment more accessible."
Now in its ninth year, Forbes 30 Under 30 celebrates and highlights young entrepreneurial leaders and game changers across 20 categories. Over 15,000 submissions were received for the list's limited 600 slots, resulting in a highly competitive 4 percent acceptance rate.
Torigen uses the animal's own tumor and tumor-associated antigens to create a personalized immunotherapy that stimulates the pet's immune system to fight the disease. For both pet owners and veterinarians, this is another tool in the toolbox to ultimately help animals live happy, healthy lives. Since its founding in 2016, the company has treated nearly 700 animals.
To date, Torigen has successfully raised $3.1 million in financing with backing from angel groups and early-stage venture capital firms including New York City's SoGal Ventures, The Fund and Connecticut Innovations. The company's labs are located at the University of Connecticut's Technology Incubation Program. Last year, Torigen was named 2018 Animal Health Innovator of the Year by the Kansas City Animal Health Corridor, and Kalinauskas has received numerous accolades for her contributions to the animal health industry. The company continues to add talented individuals from the animal health industry to its growing team.
"Every year, we are more inspired by the growing number of young people who have made it their mission to change the world through innovation, entrepreneurialism and drive, and this year's class is no exception," said Randall Lane, Chief Content Officer, Forbes, and creator of the Forbes Under 30 franchise. "The Forbes 30 Under 30 has become the preeminent recognition for the most up-and-coming visionaries, game changers and pioneers the world has to offer – and we can't wait to see what they accomplish next."
The complete Forbes 30 Under 30: Class of 2020 can be found here.
For more information, email [email protected], visit http://www.torigen.com or call 860-519-9956.
About Torigen Pharmaceuticals Inc.
Torigen Pharmaceuticals Inc. is focused on delivering affordable companion animal immuno-oncology products. Its initial patented product line utilizes a portion of the pet patient's tumor to create a personalized cancer vaccine. With over 10 years of supporting pre-clinical publications, the Torigen team is focused on developing innovative veterinary cancer biologics that allow the body to recognize foreign tumor-associated antigens and facilitate the reversal of immune senescence. For more information, please visit http://www.torigen.com.
Experimental autologous cancer vaccines created by Torigen Pharmaceuticals Inc. are regulated by the USDA Center for Veterinary Biologics. Torigen's Autologous Prescription Product should be used under supervision/prescription of a licensed veterinarian. Safety and efficacy have not been established.
Forbes Under 30
Forbes' Under 30 is a global platform that comprises Forbes Under 30 lists featuring young game changers published in print and online all over the world; live summits in the United States, Asia, Europe and Israel; and an Under 30 channel on Forbes.com.
SOURCE Torigen Pharmaceuticals
Share this article